Profile data is unavailable for this security.
About the company
Remus Pharmaceuticals Limited is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. The Company also deals in active pharmaceutical ingredient (API). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, tablet. The therapeutic areas it works include oncology, cardiovascular, anti-diabetic, immune suppressants, anti-biotic, antibacterial, dermatology, central nervous system, and others. Its oncology products include Sorafenib Tablets, Enzalutamide Capsules, Lenalidomide Capsule, and others. Its cardiovascular products include Rivaroxaban Tablets, Ticagrelor Tablets, and others.
- Revenue in INR (TTM)2.12bn
- Net income in INR215.37m
- Incorporated2015
- Employees48.00
- LocationRemus Pharmaceuticals LtdAHMEDABAD 380058IndiaIND
- Phone+91 7 929999857
- Websitehttps://remuspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kopran Ltd | 6.36bn | 528.93m | 10.03bn | 358.00 | 15.68 | 2.02 | 14.86 | 1.58 | 13.26 | 13.26 | 150.57 | 103.15 | 0.8922 | 2.76 | 3.64 | 17,765,300.00 | 7.42 | 8.47 | 10.49 | 12.23 | 35.38 | 32.93 | 8.32 | 8.89 | 1.27 | 29.83 | 0.1997 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Ngl Fine Chem Ltd | 3.72bn | 413.64m | 11.05bn | 390.00 | 26.72 | 3.94 | 29.05 | 2.97 | 66.95 | 66.95 | 601.51 | 453.70 | 1.03 | 4.37 | 5.12 | 9,529,503.00 | 11.51 | 15.06 | 14.90 | 19.58 | 51.59 | 43.53 | 11.13 | 13.15 | 2.17 | 25.70 | 0.1594 | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Bajaj Healthcare Ltd | 5.08bn | -101.06m | 12.42bn | 944.00 | -- | 2.78 | 68.66 | 2.44 | -3.70 | -5.69 | 183.39 | 141.16 | 0.6186 | 1.54 | 2.33 | 5,379,316.00 | -1.23 | 7.67 | -2.35 | 14.11 | 47.51 | 33.26 | -1.99 | 7.99 | 1.21 | 1.95 | 0.3158 | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
| Lincoln Pharmaceuticals Ltd | 5.97bn | 966.39m | 12.49bn | 1.70k | 12.92 | 1.95 | 11.50 | 2.09 | 48.25 | 48.25 | 298.31 | 319.16 | 0.828 | 3.77 | 3.40 | 3,514,339.00 | 13.39 | 13.95 | 15.85 | 16.54 | 52.60 | 50.65 | 16.18 | 14.71 | 3.64 | 60.48 | 0.0021 | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Bliss GVS Pharma Ltd | 8.00bn | 634.20m | 12.71bn | 831.00 | 20.30 | 1.26 | 12.76 | 1.59 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 13.88bn | 48.00 | 63.11 | 15.99 | 51.67 | 6.53 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 1.98bn | -242.34m | 14.72bn | 445.00 | -- | -- | 3,152.02 | 7.43 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 15.29bn | 1.03k | 64.24 | 7.75 | 53.59 | 6.74 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| JG Chemicals Ltd | 7.57bn | 550.05m | 16.18bn | 56.00 | 27.97 | 3.71 | 25.94 | 2.14 | 14.77 | 14.77 | 202.34 | 111.33 | -- | -- | -- | 135,230,700.00 | -- | -- | -- | -- | 17.29 | -- | 7.56 | -- | 11.46 | -- | 0.0281 | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Sigachi Industries Ltd | 4.36bn | 660.99m | 16.60bn | 991.00 | 29.53 | 3.52 | 21.35 | 3.81 | 1.69 | 1.69 | 11.11 | 14.15 | 0.6266 | 3.01 | 3.27 | 4,396,491.00 | 9.36 | 14.77 | 13.25 | 19.57 | 50.50 | 50.30 | 14.93 | 14.92 | 1.39 | 6.47 | 0.2576 | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Syncom Formulations (India) Ltd | 3.29bn | 331.47m | 18.97bn | 802.00 | 49.71 | 6.05 | 49.28 | 5.76 | 0.406 | 0.406 | 3.49 | 3.34 | 0.8485 | 6.21 | 3.62 | 4,105,761.00 | 8.54 | 7.50 | 10.99 | 10.23 | 38.49 | 34.10 | 10.07 | 9.38 | 4.09 | 12.05 | 0.0435 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
